Our editorial team dissects the latest developments in the ongoing story of how evolving US tariffs could impact the ...

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

Mural Oncology is halting development of its lead IL-2 therapy and enacting major layoffs after its second trial failure this ...

J&J is projecting a $400m hit due to US tariffs in 2025, but reaffirmed its profit outlook while raising its sales forecast.

Boehringer and Cue Biopharma have entered a strategic research partnership and licence agreement for the latter’s CUE-501.

AD is a growing market with an impressive pipeline of new products from current and future players in the field.

Irish medical and pharmaceutical exports to the US have seen a surge, with a year-on-year increase above 450% in February ...

Eisai and Biogen have received marketing authorisation from the European Commission (EC) for Leqembi (lecanemab) to treat Alzheimer's.